TVGN

MKT CAP:$31M

Tevogen Bio Holdings Inc.

Market Cap

$31M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$7.01-$11.18 (-61.46%)

Apr 23, 2026

Company Details

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is des...

CEO

Ryan H. Saadi

IPO Date

Jan 5, 2022

Website

tevogen.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$26M

EPS (Diluted)

-$7.49

Free Cash Flow

-$12M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 15, 2026

PENDING

FY 2025

Mar 31, 2026

$0EPS -$8.08

Q4 2025

Mar 31, 2026

$0EPS -$1.20

Q3 2025

Nov 14, 2025

$0EPS -$1.50

Q2 2025

Aug 14, 2025

$0EPS -$1.53

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$0	$0	-$11.3K
Q3 21	$0	$0	-$115
Q4 21	$0	$0	-$170.0K
Q1 22	$0	$0	-$282.9K
Q2 22	$0	$0	-$258.6K
Q1 23	$0	$0	-$2M
Q2 23	$0	-$92.7K	-$2M
Q3 23	$0	-$93.6K	-$2M
Q4 23	$0	-$100.9K	-$2M
Q1 24	$0	-$98.3K	-$30M
Q3 24	$0	-$101.7K	-$6M
Q4 24	$0	-$103.5K	-$9M
Q1 25	$0	-$105.4K	-$10M
Q2 25	$0	-$290.8K	-$5M
Q3 25	$0	-$27.2K	-$6M
Q4 25	$0	-$85.8K	-$5M

Valuation

Quarter	P/S	P/E
Q2 21	—	—
Q3 21	—	—
Q4 21	—	—
Q1 22	—	—
Q2 22	—	2939.3x
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$713.8K	-$713.8K
Q1 22	-$113.0K	-$113.0K
Q2 22	-$45.9K	-$45.9K
Q1 23	-$2M	-$2M
Q2 23	-$2M	-$2M
Q3 23	-$2M	-$2M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q3 24	-$4M	-$4M
Q4 24	-$3M	-$3M
Q1 25	-$3M	-$3M
Q2 25	-$3M	-$3M
Q3 25	-$4M	-$4M
Q4 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q4 21	$4
Q1 22	$5
Q2 22	$1
Q1 23	$133.0K
Q2 23	$1
Q3 23	$2
Q4 23	$2
Q1 24	$0
Q3 24	$0
Q4 24	$4
Q1 25	$3
Q2 25	$3
Q3 25	$4
Q4 25	$64.4K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	—	+2188.6%
Q1 23	—	+2021014.8%
Q2 23	—	+1184.9%
Q3 23	—	+721.9%
Q4 23	—	+677.0%
Q1 24	—	+1169.9%
Q3 24	—	+178.6%
Q4 24	—	+302.7%
Q1 25	—	+415.4%
Q2 25	—	-81.6%
Q3 25	—	-5.9%
Q4 25	—	-50.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$0	—
Q1 22	$0	—
Q2 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$26M	—
Q3 24	$3M	—
Q4 24	$0	—
Q1 25	$7M	—
Q2 25	$3M	—
Q3 25	$0	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 21	—	—	$11.3K
Q3 21	—	—	$115
Q4 21	—	—	$170.0K
Q1 22	—	—	$282.9K
Q2 22	—	—	$258.6K
Q1 23	$1M	$977.1K	—
Q2 23	$1M	—	$1M
Q3 23	$1M	—	$1M
Q4 23	$908.0K	—	$1M
Q1 24	$21M	$9M	—
Q3 24	$3M	—	$3M
Q4 24	$3M	—	$6M
Q1 25	$3M	—	$7M
Q2 25	$3M	—	$2M
Q3 25	$3M	—	$3M
Q4 25	$2M	$3M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$231.5K	$0	$231.5K
Q2 22	$185.6K	$0	$185.6K
Q3 22	$143.0K	$0	$143.0K
Q4 22	$5M	$0	$5M
Q1 23	$52.3K	$0	$52.3K
Q2 23	$3M	$0	$3M
Q3 23	$3M	$0	$3M
Q4 23	$1M	$0	$1M
Q1 24	$1M	$0	$1M
Q2 24	$1M	$0	$1M
Q3 24	$2M	$0	$2M
Q4 24	$1M	$0	$1M
Q1 25	$2M	$0	$2M
Q2 25	$685.2K	$0	$685.2K
Q3 25	$1M	$0	$1M
Q4 25	$552.4K	$0	$552.4K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	930K	—	—
Q3 21	930K	0.0%	—
Q4 21	959K	+3.1%	—
Q1 22	959K	0.0%	—
Q2 22	959K	0.0%	+3.1%
Q1 23	2M	+150.3%	+158.2%
Q2 23	3M	+15.9%	+190.1%
Q3 23	3M	+13.7%	+229.9%
Q4 23	3M	+2.3%	+237.5%
Q1 24	3M	-12.0%	+18.7%
Q3 24	3M	+19.5%	+22.4%
Q4 24	4M	+4.6%	+12.6%
Q1 25	3M	-9.3%	-0.2%
Q2 25	4M	+14.2%	+29.4%
Q3 25	4M	+6.4%	+15.2%
Q4 25	3M	-15.3%	-6.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	—	—
Q3 21	—	—
Q4 21	$0	3
Q1 22	$0	3
Q2 22	$0	3
Q1 23	$0	3
Q2 23	$0	3
Q3 23	$0	3
Q4 23	$0	17
Q1 24	$0	17
Q3 24	$0	17
Q4 24	$0	18
Q1 25	$0	18
Q2 25	$0	18
Q3 25	$0	18
Q4 25	$0	18

Revenue / Employee